Key Takeaways from 2026 Orphan Drugs Webinar

With a predicted 21% of all prescription drug sales by 2032, orphan drugs are poised to play a crucial role in the pharmaceutical industry, as per Evaluate forecasts. Following a recent webinar on the future of the orphan drugs market, three key takeaways have emerged about this thriving sector. If you missed the webinar, you can catch the recorded version here.

1. Orphan drugs are pivotal in dealmaking
   Dealmaking is a vital process in the broader pharmaceutical market, and this applies equally to orphan drugs. With rising competition for quality pipelines and decreasing availability of late-stage assets, orphan drugs are becoming decisive in licensing and M&A choices. Interestingly, every drug predicted to be in the top ten by 2032 was either obtained through acquisition or in-licensed. Smaller biotech firms are leveraging rare disease assets to secure partners earlier, whereas larger corporations are seeking to invest in orphan franchises that offer scalability.
2. Positive yet complex regulatory landscape
   There is no denying the prevailing uncertainty, especially in the United States. Regulatory decisions seem less consistent, and recent hiccups have dented the industry’s confidence. However, the incentive structure that drives orphan drug development is still in place, and the recent adjustment to the Inflation Reduction Act bodes well for rare disease players. Despite the rising approval benchmark, policy adjustments and rejuvenated programs remain supportive of investment. The number of significant deals executed in the orphan space over the past year indicates that companies are not overly concerned about the FDA’s volatility, at least for the time being.
3. Globalization of Innovation
   Discussion on the topic naturally included China. As Melanie and Andreas concurred, China is no longer just an emerging subject but a focal point in any conversation about orphan drug pipelines. China-originated drugs are expected to be in the top ten by 2032, while the country is also developing its own gene therapies at an impressively efficient pace. The competitive landscape in China is intense, with the leading two companies typically surviving amidst numerous firms working on similar projects. How Western developers and governments adapt to this evolution remains to be seen.

Throughout my tenure with Evaluate’s orphan drugs report, it has been fascinating to witness the transition of orphan drugs from a niche to a mainstream category. Although the market share of therapies for rare diseases seems to be reaching its pinnacle, they continue to influence the strategies of key players. The approach to these previously niche drugs now mirrors that of mainstream blockbusters, with lifecycle management, portfolio strategy, and strategic dealmaking being crucial in this high-risk, high-reward market segment.

If you wish to delve deeper into the discussion, I recommend watching the full webinar. You can also refer to the report for a more detailed numeral analysis.